Board MeetingOutcome of Board Meeting
Alivus Life Sciences' board has approved audited financial results for Q4 & FY26, reporting revenue of ₹2,551.83 Cr and profit of ₹564.48 Cr.
Alivus Life Sciences LimitedALIVUS · Filed with the exchange
They also proposed a final dividend of ₹5 per share, pending shareholder approval.
No comments yet. Be the first.